Wikisage, the free encyclopedia of the second generation, is digital heritage

Difference between revisions of "Belzutifan"

From Wikisage
Jump to navigation Jump to search
(Created page with "Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease. Belzutifan is an inhibitor of hypoxia-inducible facto...")
 
(ATC)
Line 7: Line 7:
 
==ATC==
 
==ATC==
 
<gallery>File:Belzutifan.png</gallery>
 
<gallery>File:Belzutifan.png</gallery>
 +
 +
{{wikidata|Q27456641}}

Revision as of 23:19, 13 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

Q27456641 op Wikidata  Interwiki via Wikidata